
The Infectious Disease Threat and Laboratory Biosafety

Training Seminar on Laboratory Biosecurity and Biosafety

Manila, Philippines

12 July 2006

And

Cebu, Philippines

17 July 2006

www.biosecurity.sandia.gov




SAND No. 2006-2174C

Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin Company,
for the United States Department of Energy's National Nuclear Security Administration
under contract DE-AC04-94AL85000.

The Infectious Disease Threat

- Recent outbreaks of emerging infectious disease awakened the international community to threats to public and agricultural health
- Most threat mitigation strategies have focused on outbreak management
- Measures must also be developed to *prevent* outbreaks of highly infectious disease
- Laboratory biosafety is one aspect of the solution
 - Ensures the safety and well being of workers in the laboratory
 - Safeguards public and agricultural health by preventing the accidental release of harmful biological agents




SARS virus



Today, the infectious disease threat is a global problem that requires global solutions

Severe Acute Respiratory Syndrome (SARS)

- In 2003, SARS infected over 8,000 people and killed almost 800
- The disease ravaged economies in the Pacific Rim and Canada and struck fear across the globe
- Laboratory acquired SARS outbreaks occurred in Singapore, Taiwan, and mainland China
 - Singapore—September 2003
 - Taiwan (China)—December 2003
 - Beijing and Anhui (China)—March 2004



Summary of the WHO Investigation, Singapore

- **The graduate student acquired the infection in the BSL-3 laboratory in the Environmental Health Institute where he worked**
- **Inappropriate laboratory procedures and a cross-contamination of West Nile virus samples with SARS-CoV in the laboratory led to the infection**
- **No evidence could be found of any other source of infection**
- **Isolated event: no evidence of secondary transmission**

Laboratory-Acquired Case of SARS

Taiwan (China), December 2003

- Patient: 44-year-old male laboratory scientist
- Place of infection: BSL-4 laboratory, Institute of Preventative Medicine (IPM), National Defense Medical Center (NDMC)
- Onset of illness: December 11, 2003
- Hospitalization: December 16, 2003
- Confirmed day: December 17, 2003



Summary of WHO Investigation, Taiwan (China)

- **Scientist was working on SARS-CoV in a BSL-4 facility at the IPM-NDMC**
- **He found a spillage of material in the transportation chamber and disinfected it with 70% ethanol and cleaned it manually**
- **The environment specimens collected from the handle of an alcohol spray bottle from the transportation chamber and the switch panel of the cabinet yielded positive results for SARS-CoV**
- **Isolated event: no evidence of secondary transmission**


Laboratory-Acquired SARS Outbreak in China, March-April 2004

- Occurred in Beijing and Anhui Province, to the National Institute of Virology,
- The source of the outbreak was failed or inactivation of SARS-CoV
- Involved two verified chains of SARS-CoV transmission
 - Three generations, resulting in 9 cases
- Serological analysis on the laboratory staff revealed three more seroconverted cases and one of them is most likely to have been infected early in February 2004



Laboratory-Acquired SARS Outbreak in China, March-April 2004

- A (female research student) 25 March



- I (male laboratory researcher) 17 April

SARS IgG (+)

J (female laboratory worker in BSL-3 laboratory)

K (female laboratory worker developed pneumonia)

L (male laboratory worker, A's supervisor)


Common Problems

- **Bad practice in laboratory management**
- **Poor supervision of less experienced professionals**
- **A lack of accountability for occupational health and safety**
- **A lack of biosafety policy**
- **A lack of biosafety procedures and staff training in biosafety practice**
- **A lack of internal and external quality assurance**

Laboratory-Acquired Cases of Ebola and Tularemia


- **Ebola**

- 1994 Outbreak in Cote d'Ivoire
- Swiss zoologist performs autopsy on wild chimpanzee
- Accidental infection occurs; zoologist contracts Ebola




- **Tularemia**

- In 2004, three laboratory workers at Boston University contracted tularemia
- Concern that lax illness reporting practices could lead to outbreaks of infectious disease among the local community



Laboratory Accidents

- **27% - splashes and spills**
- **25% - needlesticks**
- **16% - cuts from sharp objects**
- **14% - animal bite/scratches**
- **13% - mouth pipetting**
- **6% - other, unknown**



From: Pike, R.M. 1976. Laboratory-associated infections: Summary and analysis of 3,921 cases. Hlth Lab Sci 13:105-114.

Laboratory-Acquired Infections

TABLE 1 Comparison of 10 most common overt laboratory-associated infections over time

| 1930–1978 ^a | | | 1979–1999 | | |
|--------------------------------|-------|--------|----------------------------|-------|----------------|
| Agent or disease ^b | Cases | Deaths | Agent or disease | Cases | Deaths |
| Brucellosis | 426 | 5 | <i>M. tuberculosis</i> | 223 | 0 |
| Q fever | 280 | 1 | Q fever | 176 | 0 |
| Hepatitis | 268 | 3 | Hantavirus | 169 | 1 |
| Typhoid fever | 258 | 20 | Arboviruses | 164 | 3 |
| Tularemia | 225 | 2 | Hepatitis B virus | 84 | 1 |
| Tuberculosis | 194 | 4 | <i>Brucella</i> sp. | 81 | 4 ^c |
| Dermatomycosis | 162 | 0 | <i>Salmonella</i> sp. | 66 | 2 ^d |
| Venezuelan equine encephalitis | 146 | 1 | <i>Shigella</i> sp. | 56 | 0 |
| Psittacosis | 116 | 10 | Hepatitis non-A, non-B | 28 | 0 |
| Coccidioidomycosis | 93 | 2 | <i>Cryptosporidium</i> sp. | 27 | 0 |
| Total | 2,168 | 48 | Total | 1,074 | 11 |

^aAdapted from Pike, 1978.

^bNot included are 113 cases of hemorrhagic fever contracted from wild rodents in one laboratory in Russia in 1962 (Kulagin, 1962).


^cAborted fetuses.

^dOne death associated with a secondary exposure case.

From: Fleming, D.O. and D.L. Hunt. *Biological Safety: Principles and Practices*. ASM Press, 2000

Laboratory Biosafety

- Provides a means to reduce outbreaks of highly infectious diseases
- WHO biosafety:
 - “Laboratory biosafety” describes containment principles, technologies, and practices implemented to prevent unintentional exposure to pathogens and toxins, or their accidental release
- Achieving biosafety
 - Important to develop national biosafety policies
 - Critical to develop a culture of biosafety



Laboratory Biosafety Manual, 3rd Edition

Strengthening Biological Risk Management



Vision for Integrated BioRisk Management:

- ✓ Increased focus on "awareness" to change current culture
- ✓ Clarify terminology
- ✓ Development of targeted "training strategies"
- ✓ Securing "commitment" from key stakeholders, including government officials, who must be on board
- ✓ Continue increasing "capacity" based on Regional/Country needs and establish accountability through development of Country "report cards"

Conclusions

- **Infectious diseases pose significant threats to public and agricultural health**

- **Research on harmful biological agents is crucial to mitigate the threat**
 - **However, release and theft of biological agents must be avoided**
 - **Imperative to protect public and agricultural health, and safeguard laboratory workers**

- **Managing risks in the laboratory is dependent on both biosafety and biosecurity**
 - **Helps reduce the threat of infectious disease**